Tumor Type,Test,Gene mutations,Therapy
Breast cancer,FoundationOne CDx,AKT1 E17K,TRUQAP™ (capivasertib) in combination with FASLODEX® (fulvestrant)
Breast cancer,FoundationOne CDx,"PIK3CA R88Q, N345K, C420R, E542K, E545A, E545D, E545Q, E545K, E545G, Q546E, Q546K, Q546R, Q546P, M1043V, M1043I, H1047Y, H1047R, H1047L, G1049R;",TRUQAP™ (capivasertib) in combination with FASLODEX® (fulvestrant)
Breast cancer,FoundationOne CDx,PTEN alterations,TRUQAP™ (capivasertib) in combination with FASLODEX® (fulvestrant)
Breast cancer,FoundationOne CDx,ERBB2 (HER2) amplification,HERCEPTIN® (trastuzumab)
Breast cancer,FoundationOne CDx,ERBB2 (HER2) amplification,KADCYLA® (ado-trastuzumab emtansine)
Breast cancer,FoundationOne CDx,ERBB2 (HER2) amplification,PERJETA® (pertuzumab)
Breast cancer,FoundationOne CDx,"PIK3CA mutations C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y",PIQRAY® (alpelisib) in combination with fulvestrant
Cholangiocarcinoma,FoundationOne CDx,FGFR2 fusions and select rearrangements,PEMAZYRE® (pemigatinib)
Colorectal cancer,FoundationOne CDx,KRAS wild-type (absence of mutations in codons 12 and 13),ERBITUX® (cetuximab)
Colorectal cancer,FoundationOne CDx,"KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild-type (absence of mutations in exons 2, 3, and 4)",VECTIBIX® (panitumumab)
Melanoma,FoundationOne CDx,BRAF V600 mutation-positive,TECENTRIQ® (atezolizumab) in combination with COTELLIC® (cobimetinib) and ZELBORAF® (vemurafenib)
Melanoma,FoundationOne CDx,BRAF V600E,BRAF Inhibitor Approved by FDA*
Melanoma,FoundationOne CDx,BRAF V600E and V600K,BRAF/MEK Inhibitor Combinations Approved by FDA* or MEKINIST® (trametinib)
Non-small cell lung cancer (NSCLC),FoundationOne CDx,ALK rearrangements,ALECENSA® (alectinib)
Non-small cell lung cancer (NSCLC),FoundationOne CDx,ALK rearrangements,ALUNBRIG® (brigatinib)
Non-small cell lung cancer (NSCLC),FoundationOne CDx,ALK rearrangements,XALKORI® (crizotinib)
Non-small cell lung cancer (NSCLC),FoundationOne CDx,ALK rearrangements,ZYKADIA® (ceritinib)
Non-small cell lung cancer (NSCLC),FoundationOne CDx,BRAF V600E,BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib)
Non-small cell lung cancer (NSCLC),FoundationOne CDx,BRAF V600E,TAFINLAR® (dabrafenib) in combination with MEKINIST® (trametinib)
Non-small cell lung cancer (NSCLC),FoundationOne CDx,EGFR exon 19 deletions and EGFR exon 21 L858R alterations,EGFR Tyrosine Kinase Inhibitors (TKI) Approved by FDA*
Non-small cell lung cancer (NSCLC),FoundationOne CDx,EGFR exon 20 T790M alterations,TAGRISSO® (osimertinib)
Non-small cell lung cancer (NSCLC),FoundationOne CDx,MET single nucleotide variants (SNVs) and indels that lead to MET exon 14 skipping,TABRECTA® (capmatinib)
Non-small cell lung cancer (NSCLC),FoundationOne CDx,ROS1 fusions,ROZLYTREK® (entrectinib)
Ovarian cancer,FoundationOne CDx,"BRCA1, BRCA2 alterations",LYNPARZA® (olaparib)
Prostate cancer,FoundationOne CDx,"BRCA1, BRCA2 alterations",AKEEGA® (niraparib + abiraterone acetate)
Prostate cancer,FoundationOne CDx,"BRCA1, BRCA2 alterations",LYNPARZA® (olaparib) in combination with abiraterone
Prostate cancer,FoundationOne CDx,"Homologous Recombination Repair (HRR) gene (BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L) alterations",LYNPARZA® (olaparib)
Solid tumors,FoundationOne CDx,MSI-High,KEYTRUDA® (pembrolizumab)
Solid tumors,FoundationOne CDx,NTRK1/2/3 fusions,ROZLYTREK® (entrectinib) or VITRAKVI® (larotrectinib)
Solid tumors,FoundationOne CDx,RET fusions,RETEVMO® (selpercatinib)
Solid tumors,FoundationOne CDx,TMB ≥ 10 mutations per megabase,KEYTRUDA® (pembrolizumab)
Non-small cell lung cancer (NSCLC),FoundationOne Liquid CDx,ALK rearrangements,ALECENSA® (alectinib)
Non-small cell lung cancer (NSCLC),FoundationOne Liquid CDx,BRAF V600E ,BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib)
Non-small cell lung cancer (NSCLC),FoundationOne Liquid CDx,EGFR exon 19 deletions,EGFR tyrosine kinase inhibitors approved by FDA*
Non-small cell lung cancer (NSCLC),FoundationOne Liquid CDx,EGFR exon 21 L858R substitution,EGFR tyrosine kinase inhibitors approved by FDA*
Non-small cell lung cancer (NSCLC),FoundationOne Liquid CDx,EGFR exon 20 insertions,EXKIVITY® (mobocertinib)
Non-small cell lung cancer (NSCLC),FoundationOne Liquid CDx,MET single nucleotide variants (SNVs) and indels that lead to MET exon 14 skipping,TABRECTA® (capmatinib) or Tepmetko (tepotinib)
Non-small cell lung cancer (NSCLC),FoundationOne Liquid CDx,ROS1 fusions,ROZLYTREK® (entrectinib)
Prostate cancer,FoundationOne Liquid CDx,"BRCA1, BRCA2, ATM alterations",LYNPARZA® (olaparib)
Prostate cancer,FoundationOne Liquid CDx,"BRCA1, BRCA2 alterations",RUBRACA® (rucaparib)
Breast cancer,FoundationOne Liquid CDx,"PIK3CA mutations C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R; H1047L, H1047R, and H1047Y",PIQRAY® (alpelisib)
Solid Tumors,FoundationOne Liquid CDx,NTRK1/2/3  fusions,ROZLYTREK® (entrectinib)
Colorectal Cancer (CRC),FoundationOne Liquid CDx,BRAF V600E ,BRAFTOVI® (encorafenib) in combination with cetuximab
Low-Grade Glioma,FoundationOne Liquid CDx,BRAF V600 mutation-positive and BRAF fusions,OjemdaTM (tovorafenib)
Non-small cell lung cancer (NSCLC),Guardant360® CDx,"EGFR exon 19 deletions, L858R, and T790M*",TAGRISSO® (osimertinib)
Non-small cell lung cancer (NSCLC),Guardant360® CDx,EGFR exon 20 insertions,RYBREVANT® (amivantamab-vmjw)
Non-small cell lung cancer (NSCLC),Guardant360® CDx,ERBB2/HER2 activating mutations (SNVs and exon 20 insertions),ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Non-small cell lung cancer (NSCLC),Guardant360® CDx,KRAS G12C,LUMAKRAS™ (sotorasib)
Breast cancer,Guardant360® CDx,ESR1 missense mutations between codons 310 and 547,ORSERDU™ (elacestrant)
